

~~Sub 3~~  
--104. A polypeptide comprising an immunogenic portion of native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 or 3.

105. The polypeptide of claim 1, wherein said immunogenic portion differs from SEQ ID NO:2 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

C  
106. A mimetic of an immunogenic portion of a WT1 polypeptide, wherein at least one amino acid residue is replaced by a compound that is not an amino acid, such that the ability of the mimetic to react with antigen-specific antisera and/or T-cell lines or clones is not diminished, wherein said immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 or 3.

~~Sub 3~~  
107. A pharmaceutical composition comprising a polypeptide according to claim 104, in combination with a pharmaceutically acceptable carrier or excipient.

108. An immunogenic composition comprising a polypeptide according to claim 104, in combination with a non-specific immune response enhancer.

109. A immunogenic composition according to claim 108, wherein the immune response enhancer is an adjuvant.

110. A immunogenic composition comprising:

(a) a WT1 polypeptide, wherein the polypeptide comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions,